Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
io102
- Development stage
- Phase 2
- Lead developer
- IO Biotech
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
IO102 is a second-generation peptide-based cancer vaccine developed as an immunotherapy targeting the enzyme indoleamine 2,3-dioxygenase (IDO). It is designed to stimulate cytotoxic T lymphocyte responses against IDO-expressing cells in the tumor microenvironment. By inhibiting IDO—a key immunosuppressive enzyme often overexpressed in various cancers—IO102 aims to reduce immune suppression and enhance anti-tumor immunity. The drug is being investigated primarily in combination with other therapies such as pembrolizumab (an anti-PD-1 antibody) and sometimes with another peptide vaccine (IO103), which targets PD-L1 positive cells. Clinical trials have focused on advanced melanoma, squamous cell carcinoma of the head and neck (SCCHN), and non-small cell lung cancer (NSCLC). IO102 is administered subcutaneously.
- Other names
- io102 hydrochlorideio-102 hydrochlorideio 102 hydrochloride
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on io102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on io102.